StevanatoSTVN
About: Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.
Employees: 5,635
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
27% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 45
10% less funds holding
Funds holding: 146 [Q1] → 131 (-15) [Q2]
41% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 37
42% less capital invested
Capital invested by funds: $1.65B [Q1] → $957M (-$695M) [Q2]
42.15% less ownership
Funds ownership: 147.55% [Q1] → 105.4% (-42.15%) [Q2]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
55% less call options, than puts
Call options by funds: $28K | Put options by funds: $62K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Citigroup Patrick Donnelly 57% 1-year accuracy 13 / 23 met price target | 56%upside $28 | Buy Maintained | 7 Aug 2024 |
Financial journalist opinion
Based on 4 articles about STVN published over the past 30 days
